Brainstorm Cell Therapeutics Inc represents values such as innovation, integrity, and commitment to providing revolutionary treatments for neurological diseases. With a strong corporate philosophy focused on patient-centered care and scientific excellence, Brainstorm Cell Therapeutics Inc aims to improve the lives of individuals suffering from neurodegenerative conditions. Through their groundbreaking stem cell technology, the company strives to offer effective therapies that address the underlying causes of diseases like amyotrophic lateral sclerosis (ALS). With a relentless pursuit of advancements in regenerative medicine, Brainstorm Cell Therapeutics Inc aims to bring hope and optimize the potential for patients and their families.

Brainstorm Cell Therapeutics Inc is primarily present in the United States.

Since its establishment, Brainstorm Cell Therapeutics Inc has accomplished several noteworthy milestones. Firstly, the company successfully developed its proprietary NurOwn® technology, a stem cell-based therapy platform for neurodegenerative diseases. Additionally, Brainstorm Cell Therapeutics Inc conducted phase 1 and phase 2 clinical trials, demonstrating the safety and efficacy of NurOwn® in treating patients with amyotrophic lateral sclerosis (ALS). The company received the prestigious designation of Fast Track status from the U.S. FDA for their ALS clinical development program. Furthermore, Brainstorm Cell Therapeutics Inc has gained recognition for its innovation and commitment to improving patients' lives within the field of cell therapy.

Brainstorm Cell Therapeutics Inc. is a renowned biotechnology company specializing in the development of innovative cell-based therapies. Established in 2000, the company is dedicated to advancing treatments for neurodegenerative diseases, focusing primarily on amyotrophic lateral sclerosis (ALS). By harnessing the therapeutic potential of stem cells, Brainstorm Cell Therapeutics Inc. aims to revolutionize the field of regenerative medicine. With its cutting-edge proprietary platform, NurOwn®, the company has gained significant recognition for its groundbreaking research and clinical advancements. Brainstorm Cell Therapeutics Inc. has garnered a strong reputation in the industry, and its commitment to curing neurological disorders continues to drive its pioneering efforts.

The main competitors of Brainstorm Cell Therapeutics Inc in the market include companies such as Pluristem Therapeutics Inc, Athersys, Inc, and Vericel Corporation. These companies, like Brainstorm Cell Therapeutics Inc, are focused on the development and commercialization of innovative cell-based therapies. However, Brainstorm Cell Therapeutics Inc distinguishes itself through its unique platform technology and proprietary stem cell therapy, NurOwn®, which has shown promising results in the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).

Brainstorm Cell Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Brainstorm Cell Therapeutics Inc revolves around developing and commercializing innovative autologous cellular therapies for neurodegenerative diseases. The company specializes in their proprietary NurOwn technology platform, which aims to harness the potential of adult stem cells for the treatment of diseases like Amyotrophic Lateral Sclerosis (ALS). Brainstorm's business model focuses on conducting clinical trials to demonstrate the safety and efficacy of their therapies, seeking regulatory approvals, and partnering with biopharmaceutical companies to bring their treatments to market globally. Through their research and development efforts, Brainstorm aims to provide cutting-edge therapies that address the unmet medical needs of patients facing neurodegenerative disorders.

مُعامل القيمة السوقية إلى الأرباح لـ Brainstorm Cell Therapeutics هو ؜-١٫٢٥.

مُعامِل القيمة إلى المبيعات Brainstorm Cell Therapeutics هو 0.

نقاط جودة AlleAktien لـ Brainstorm Cell Therapeutics هي 5/10.

لا يمكن حالياً حساب الإيرادات لـBrainstorm Cell Therapeutics.

صافي الربح المتوقعة Brainstorm Cell Therapeutics هو ؜-١١٫٧٧ مليون. USD.

Brainstorm Cell Therapeutics Inc is a biotechnology company based in the USA that focuses on developing novel therapies for neurological disorders. The company's business model involves identifying, developing, and marketing advanced treatment options for patients with severe neurological conditions. The company is divided into several business divisions, including research and development, clinical studies, manufacturing, sales, and marketing. The research and development unit is responsible for identifying and developing promising therapeutic approaches for conditions such as ALS and multiple sclerosis. The clinical study unit conducts clinical trials and tests to evaluate the efficacy and safety of new therapies, while the manufacturing unit is responsible for producing the therapy products. The main product of Brainstorm Cell Therapeutics Inc is NurOwn, an autologous cell therapy developed for the treatment of ALS (Amyotrophic Lateral Sclerosis). This technology utilizes the properties of mesenchymal stem cells to release specific growth factors that support the regeneration of neurons in the nervous system. NurOwn is based on a patented process for isolating and purifying mesenchymal stem cells, which are extracted from the patient's bone marrow and then proliferated in vitro. Brainstorm Cell Therapeutics Inc works closely with research organizations and medical institutions to promote the development and marketing of NurOwn and other therapeutic approaches. The company has established a strong partnership with Hadassah University Hospital in Israel, a leading medical research center known for its pioneering work in developing and applying novel therapies for ALS. The commercial strategy of Brainstorm Cell Therapeutics Inc includes marketing its products to medical professionals and relevant organizations in various European countries, including Germany, France, Italy, Spain, and the United Kingdom. The company is also working on expanding its presence in new markets and regions through strategic partnerships with other biopharmaceutical companies. Overall, Brainstorm Cell Therapeutics Inc aims to become a leading biopharmaceutical company for the development of cell therapies for neurological disorders. The company is actively working to demonstrate the potential of its innovative therapeutic approaches in treating ALS and other neurological conditions and to bring its products to new markets to help patients worldwide.

يوزع Brainstorm Cell Therapeutics أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Brainstorm Cell Therapeutics في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـBrainstorm Cell Therapeutics هو US10501E2019.

رمز WKN لـ Brainstorm Cell Therapeutics هو A12BXW.

الرمز المُختصر لـ Brainstorm Cell Therapeutics هو BCLI.

خلال آخر 12 شهراً، دفعت Brainstorm Cell Therapeutics توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Brainstorm Cell Therapeutics خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Brainstorm Cell Therapeutics هي .

Brainstorm Cell Therapeutics يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Brainstorm Cell Therapeutics دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Brainstorm Cell Therapeutics يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Brainstorm Cell Therapeutics المُعلن عنها في ١٧‏/٨‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١٧‏/٨‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١٧‏/٨‏/٢٠٢٤.

في العام 2023، وزعت Brainstorm Cell Therapeutics 0 USD كأرباح أسهم.

يتم توزيع أرباح Brainstorm Cell Therapeutics بالعملة USD.